We are live on ! Find out more
FCM

Farallon Capital Management Portfolio holdings

AUM $17.5B
1-Year Est. Return 50.95%
This Fund
S&P 500
This Quarter Est. Return
+4.27%
1 Year Est. Return
+50.95%
3 Year Est. Return
+148.38%
5 Year Est. Return
+206.05%
10 Year Est. Return
+1,475.31%
AUM
$7.45B
AUM Growth
+$600M
Cap. Flow
+$485M
Cap. Flow %
6.51%
Top 10 Hldgs %
47.64%
Holding
120
New
28
Increased
23
Reduced
22
Closed
26

Sector Composition

Rank Sector Weight
1 Healthcare 19.32%
2 Communication Services 16.41%
3 Technology 11.04%
4 Industrials 9.98%
5 Consumer Discretionary 8.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ABBV icon
51
AbbVie
ABBV
$443B
$19.1M 0.26%
+285,000
New +$18.6M
BABA icon
52
Alibaba
BABA
$293B
$18.2M 0.24%
221,000
GTI
53
DELISTED
GRAFTECH INTERNATIONAL LTD
GTI
$17.4M 0.23%
+3,514,300
New +$16.6M
GRFS
54
Grifois
GRFS
$5.36B
$17.2M 0.23%
1,110,668
+531,292
+92% +$8.61M
A icon
55
Agilent Technologies
A
$39.1B
$17.2M 0.23%
445,000
-70,000
-14% -$2.91M
TTPH
56
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$16.5M 0.22%
17,400
+4,250
+32% +$3.47M
AAL icon
57
American Airlines Group
AAL
$10.1B
$16M 0.21%
400,000
KN icon
58
Knowles
KN
$3.13B
$15.6M 0.21%
860,000
-949,000
-52% -$18.4M
WMGI
59
DELISTED
Wright Medical Group Inc
WMGI
$15.4M 0.21%
585,000
-70,000
-11% -$1.85M
NVET
60
DELISTED
Nexvet Biopharma plc Ordinary Shares
NVET
$12.4M 0.17%
2,499,996
ATML
61
DELISTED
ATMEL CORP
ATML
$12M 0.16%
+1,215,000
New +$10.7M
CLUB
62
DELISTED
Town Sports International Holdings, Inc.
CLUB
$11.8M 0.16%
4,060,082
OREX
63
DELISTED
Orexigen Therapeutics, Inc.
OREX
$11.7M 0.16%
237,200
+90,500
+62% +$5.41M
BRLI
64
DELISTED
BIO-REFERENCE LABS INC-NEW-
BRLI
$10.1M 0.14%
+245,000
New +$8.78M
PCO
65
DELISTED
Pendrell Corporation - Class A
PCO
$9.27M 0.12%
6,768
YELP icon
66
Yelp
YELP
$1.45B
$9.25M 0.12%
+215,000
New +$9.97M
DISH
67
DELISTED
DISH Network Corp.
DISH
$9.14M 0.12%
+135,000
New +$9.43M
LRMR icon
68
Larimar Therapeutics
LRMR
$397M
$7.96M 0.11%
19,167
+8,334
+77% +$3.49M
STML
69
DELISTED
Stemline Therapeutics, Inc.
STML
$7.92M 0.11%
672,562
GILD icon
70
Gilead Sciences
GILD
$162B
$7.9M 0.11%
+67,500
New +$7.38M
INXN
71
DELISTED
Interxion Holding N.V.
INXN
$7.54M 0.1%
272,500
-57,500
-17% -$1.71M
GWPH
72
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$7.37M 0.1%
+60,000
New +$6.81M
PRE
73
DELISTED
PARTNERRE LTD
PRE
$7.08M 0.1%
+55,112
New +$7.11M
KMI.WS
74
DELISTED
Kinder Morgan Inc
KMI.WS
$6.75M 0.09%
2,500,000
VIRX
75
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$6.51M 0.09%
+10,301
New +$5.47M

Similar funds

Farallon Capital Management's Q2 2015 Portfolio in Review

As of Q2 2015, Farallon Capital Management held 120 positions worth $7.45B, up 8.8% from $6.85B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Farallon Capital Management deployed $485M of net new capital in Q2 2015, opening 28 new positions and adding to 23 existing holdings. Its largest new stake was CATAMARAN CORP COM STK (CDA): 6,817,500 shares worth $416M.

By sector, the portfolio is most concentrated in Healthcare at 19% of assets, up from 9.9% a quarter earlier, followed by Communication Services and Technology.

On the sell side, the largest reduction was Hudson Pacific Properties, an estimated $157M trimmed.

  • Farallon Capital Management's largest Q2 2015 buy was CATAMARAN CORP COM STK (CDA): 6,817,500 shares worth $416M.
  • Farallon Capital Management added most to HOSPIRA INC in Q2 2015, an estimated $458M increase.
  • Farallon Capital Management's biggest Q2 2015 reduction was Hudson Pacific Properties, cutting an estimated $157M.
  • Farallon Capital Management fully exited PHARMACYCLICS INC in Q2 2015, selling an estimated $498M.
  • Farallon Capital Management's ten largest holdings make up 48% of its $7.45B portfolio in Q2 2015.
  • Farallon Capital Management opened 28 new positions and closed 26 in Q2 2015.
  • Farallon Capital Management's portfolio value rose 8.8% quarter-over-quarter to $7.45B.

Based on Farallon Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.